Intra-Arterial Tenecteplase After Clot Removal for Stroke
Treatments studied
Part of Brain & nervous system, Heart & circulation clinical trials.
This trial tests whether giving a clot-busting drug called tenecteplase directly into the brain artery after a successful mechanical clot removal can improve recovery for people with a certain type of stroke. The goal is to see if it safely helps clear any remaining tiny clots and reduces disability.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You are between 18 and 85 years old.
- You had a stroke caused by a blockage in a large artery in the front of your brain.
- The clot removal procedure was started within 24 hours of when you were last known to be well.
- The clot removal was successful (blood flow restored to at least 2b out of 3) and required 5 or fewer passes with the device.
- You do not have a bleeding disorder, are not on blood thinners that would increase bleeding risk, and have not had recent major surgery or a prior bleeding stroke.
- You are able to provide written consent (or have a family member do so).
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a clot-busting drug called tenecteplase given directly into the brain artery for people having a moderate stroke caused by a blockage in a medium-sized blood vessel. The goal is to see if it helps improve recovery when given within 24 hours of stroke symptoms starting.
This trial looks at giving a clot-busting medicine directly into the brain arteries (intra-arterial TNK) when a stroke procedure (thrombectomy) doesn’t reopen the blocked vessel enough. It aims to improve recovery by improving blood flow while checking for safety, especially bleeding risk.
This trial tests if giving a clot-busting drug (tenecteplase) directly into the brain artery after a successful clot-removal procedure can improve outcomes for people with a major stroke. It is for patients who had a large vessel blockage and received endovascular thrombectomy within 24 hours of symptoms starting.
This study tests a clot-dissolving drug called tenecteplase given directly into the artery after a mechanical thrombectomy (clot removal). The goal is to see if it helps improve blood flow to the small vessels in the brain after the main clot is removed.
This study tests whether giving a clot-busting drug called tenecteplase directly into the brain's blood vessels can help complete the removal of a clot after a first attempt at mechanical extraction was only partially successful.
This trial tests whether giving tenecteplase directly into the brain artery after a thrombectomy can improve outcomes when blood flow doesn’t fully return (“no-reflow”) in an emergency stroke. It may help some people by reducing ongoing clot-related blockage after the main clot is removed.
Hear when a new Ischemic Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.